Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide

Journal of Surgical Oncology

Volumn 64, Issue 1, 1997, Pages 17-22

  Elias, E George ^a,b   Suter, Charles M ^a   Fabian, Dagmar S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

adjuvant therapy; autologous vaccine; melanoma; revaccination

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MALE; MELANOMA; PRIORITY JOURNAL; SUPPRESSOR CELL; VACCINATION;

EID: 0031050266     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199701)64:1<17::AID-JSO4>3.0.CO;2-S     Document Type: Article

References (21)

1. Ketcham AS, Moffat FL, Balch CM: Classification and staging. In Balch CM, Haughton AN, Milton GW, Soeber AJ, Soong SJ, (eds): "Cutaneous melanoma." Philadelphia: J.B. Lippincott, 1992:213-220.
2. Balch CM, Soong ST, Murad TM, et al: A multifactorial analysis of melanoma: III. Prognostic factors, in melanoma patients with lymph node metastases. Ann Surg 1981;193:377-388.
3. Elias EG, Didolkar MS, Goel IP, et al: A clinicopathologic study of prognostic factors in cutaneous malignant melanoma. Surg Gynec Obstet 1977;144:327-334.
4. Kirkwood J, Hunt M, Smith T, et al: A randomized control trial of high dose INF alfa-2b for high risk melanoma. The ECOG trial EST 1684. Proc Ann Meeting Am Soc Clin Oncol 1993;2:A1331.
5. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9:1403-1408.
6. Pyrthonen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992;10:1919-1926.
7. Kirkwood JM, Logan TF, Vlock DR, et al: Biological response modifiers in the therapy of metastatic melanoma. In Rumke P (ed). "Therapy of advanced melanoma: pigmented cells," Vol. 10. Basel, Switzerland: Karger, 1990:105-140.
8. Barth A, Morton DL: The role of adjuvant therapy in melanoma management. Cancer 1995;75(2 Suppl):726-734.
9. Elias EG, Tomazic VJ, Buda BS: Adjuvant immunotherapy in melanoma: a new approach. J Surg Oncol 1992;50:144-148.
10. Darrow TL, Slingluff CL, Seigler HF: The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J Immunol 1989;142:3329-3335.
11. Berd D, Mastrangelo MJ: Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+ and 2H4+ suppressor-inducer T-cells. Cancer Res 1988;48:1671-1675.
12. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ: "Manual for staging of cancer." Philadelphia: J.B. Lippincott, 1993.
13. Fidler IJ, Kripke ML: Metastasis results from pre-existing variant cells within a malignant tumor. Science 1977;197:893-895.
14. Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980;40:2281-2287.
15. Fidler IR, Hart IR: Biologic diversity in metastatic neoplasms -origins and implications. Science 1982;217:998-1001.
16. Nicolson GL: Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988;7:143-188.
17. Kirkwood JM, Strawden MM, Ernstoff MS, et al: Interferon alfa 2-b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial. EST-1684. J Clin Oncol 1996;14:7-17.
18. Morton D, Hoon D, Nizze J, et al: Polyvalent vaccine improves survival of patients with metastatic melanoma. Ann Surg 1992; 216:463-482.
19. Mitchell MS, Harel W, Kan-Mitchell J, et al: Active specific immunotherapy of melanoma with allogenic cell lysates. Ann NY Acad Sci 1993;690:153-166.
20. Levington P: Approaches to augmenting the IgG antibody response to melanoma ganglioside vaccines. Ann NY Acad Sci 1993;690:204-213.
21. Berd D, Maguire H, Mastrangelo M: Treatment of human melanoma with hapten modified autologus vaccine. Ann NY Acad Sci 1993;690:147-150.